KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $765000.0.

  • Neogenomics' Cash from Financing Activities fell 3500.42% to $765000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$200.0 million, marking a year-over-year decrease of 392543.51%. This contributed to the annual value of $4.6 million for FY2024, which is 202.02% up from last year.
  • As of Q3 2025, Neogenomics' Cash from Financing Activities stood at $765000.0, which was down 3500.42% from -$202.4 million recorded in Q2 2025.
  • Neogenomics' Cash from Financing Activities' 5-year high stood at $524.9 million during Q1 2021, with a 5-year trough of -$202.4 million in Q2 2025.
  • Its 5-year average for Cash from Financing Activities is $28.7 million, with a median of $1.3 million in 2023.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 8497860.62% in 2021, then tumbled by 1039669.38% in 2025.
  • Quarter analysis of 5 years shows Neogenomics' Cash from Financing Activities stood at $2.5 million in 2021, then decreased by 26.75% to $1.8 million in 2022, then decreased by 29.52% to $1.3 million in 2023, then plummeted by 45.91% to $687000.0 in 2024, then grew by 11.35% to $765000.0 in 2025.
  • Its Cash from Financing Activities was $765000.0 in Q3 2025, compared to -$202.4 million in Q2 2025 and $949000.0 in Q1 2025.